ScholarLens Back to search
2010•Chinese Journal of New Drugs and Clinical RemediesRequires access

Advances of dipeptidyl peptidase IV inhibitors in diabetes mellitus

Xiao‐cong Zuo

Open publisher page 0 citations

Abstract

Dipeptidyl peptidase IV(DPP-IV) inhibitor is a new type of oral hypoglycemic agents for the treatment of patients with type 2 diabetes.Inhibition of the enzyme DPP-IV results in decreased degradation of both glucagon-like peptide-1(GLP-1) and glucose-dependent insulinotropic peptide(GIP).Through the action of GLP-1 and GIP,DPP-IV inhibitors can enhance insulin secretion,control the blood glucose level and protect the function of β-cell.This article reviews the research status and future therapeutic potential of this new type of drug.

About this research paper

What this paper is about

Dipeptidyl peptidase IV(DPP-IV) inhibitor is a new type of oral hypoglycemic agents for the treatment of patients with type 2 diabetes.Inhibition of the enzyme DPP-IV results in decreased degradation of both glucagon-like peptide-1(GLP-1) and glucose-dependent insulinotropic peptide(GIP).Through the action of GLP-1 and GIP,DPP-IV inhibitors can enhance insulin secretion,control the blood glucose level and protect the function of β-cell.This article reviews the research status and future therapeutic potential of this new type of drug.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Dipeptidyl peptidase IV(DPP-IV) inhibitor is a new type of oral hypoglycemic agents for the treatment of patients with type 2 diabetes.Inhibition of the enzyme DPP-IV results in decreased degradation of both glucagon-like peptide-1(GLP-1) and glucose-dependent insulinotropic peptide(GIP).Through the action of GLP-1 and GIP,DPP-IV inhibitors can enhance insulin secretion,control the blood glucose level and protect the function of β-cell.This article reviews the research status and future therapeutic potential of this new type of drug.

Key concepts: Dipeptidyl peptidase, Dipeptidyl peptidase-4, Glucagon-like peptide-1, Type 2 Diabetes Mellitus, Medicine, Internal medicine, Insulin, Type 2 diabetes

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Advances of dipeptidyl peptidase IV inhibitors in diabetes mellitus — Research Paper | ScholarLens